Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside. On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress across the company’s clinical pipeline. The firm reflected on the topline readout from the Phase 3 OPUS-1 trial, expected in the fourth quarter of 2026, with a planned BLA filing the following year. OPUS-2 has already begun participant dosages, and OPUS-3 is set to start i ...